NEW YORK, NY--(Marketwired - Apr 4, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) welcomes the month of April with a brand new state of the art production facility that is due to be fully operational sometime this month. Plandaí recently finished the all-important Stage 2 on the Senteeko Tea Estate in South Africa. It's this section of the factory that CEO Roger Duffield says "the magic of Phytofare" takes place. Plandaí will make its money and its mark in the biotechnology sector here as it's where the proprietary hydrodynamic sheering process will takes place.
Plandaí and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. In order to develop these highly bioavailable extracts, it requires Plandaí's unique extraction process that uses live plant material grown on the tea estate and a combination of temperature and a unique wave of acoustic energy to release the living phytonutrients, rearranging the polyenes into a bio-compatible form.
Plandaí's CEO said of this process, "The magic of Phytofare involves unzipping the molecule to release the valuable phytonutrients, which we have now done for the first time on an industrial scale."
So, with stage 1 and 2 done, the company has turned to completing stage 3, the only section remaining between Plandaí and the introduction of its Phytofare™ extracts to the public. The third stage of Plandaí's process separates out the solids and any unnecessary elements, rendering pharmaceutical-grade, purified catechins in mainly nano-particle form.
As Plandaí reaches the finish line on the production facility, Duffield said, "It is exciting to see the culmination of over ten years of research and effort on the part of countless supporters."
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. SMMG is compensated for Plandaí articles, reports and interviews by a third party who reserves the right to buy, sell or remain neutral on securities at any time before, during, or after the publication of this article. To date, SMMG has received total compensation of $39,190, for content related to Plandaí. For more information: www.stockmarketmediagroup.com/disclaimer.